CSTL - Castle Biosciences Inc

CSTL - Castle Biosciences Inc

https://castlebiosciences.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Castle Biosciences to Participate in Upcoming Investor Conferences - Castle Biosciences ( NASDAQ:CSTL )

Benzinga • 3 weeks, 4 days ago • score: 0.63

FRIENDSWOOD, Texas, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference ...

Castle Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire • 3 weeks, 4 days ago • score: 0.64

Castle Biosciences will participate in three investor conferences in September ...

Castle Biosciences, Inc. ( CSTL ) Q2 Earnings and Revenues Surpass Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.08

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 1st

Zacks Commentary • 1 month, 2 weeks ago • score: -0.22

CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire • 1 month, 2 weeks ago • score: 0.69

Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

None

52W High

$35.84

52W Low

$14.59

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.07

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

13.66

EV/Revenue (<3 favorable)

1.29

P/S (TTM) (<3 favorable)

1.97

P/B (<3 favorable)

1.50

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.90%

Institutions (25–75% balanced)

93.02%

Shares Outstanding

29,008,300

Float

26,756,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

346,269,000

Gross Profit (TTM)

280,468,000

EPS (TTM)

-0.34

Profit Margin (>10% good)

-0.03%

Operating Margin (TTM) (higher better)

-0.05%

ROE (TTM) (>15% strong)

-0.02%

EPS YoY (Quarterly) (>10% good)

-0.52

Revenue YoY (Quarterly) (>8% good)

-0.01

Momentum

Bearish momentum

Value

1.1361

Previous

1.4218

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025